bluebird bio Inc reports results for the quarter ended September 30 - Earnings Summary

bluebird bio

14/11/2024 20:58

* bluebird bio Inc  BLUE.OQ  reported a quarterly adjusted
loss
of 31 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -66 cents.  The mean expectation of ten analysts
for the quarter was for a loss of 36 cents per share. Wall
Street expected results to range from -46 cents to -28 cents per
share.
    * Revenue fell 14.4% to $10.61 million from a year ago;
analysts
expected $18.05 million. 
    * bluebird bio Inc's reported EPS for the quarter was a loss
of 31
cents​.
    * The company reported a quarterly loss of $60.81 million.
    * bluebird bio Inc shares had fallen by 27.6% this
quarter and
lost 72.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 6
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for bluebird bio Inc
is 2.50 
This summary was machine generated from LSEG data November 14 at
08:58 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.36          -0.31          Beat
 Jun. 30 2024      -0.42          -0.42          Met
 Mar. 31 2024      -0.44          -0.36          Beat
 Dec. 31 2023      -0.66          -0.78          Missed